Table 4.
Controls | PCOS | |||
---|---|---|---|---|
PP | PL+LL | PP | PL+LL | |
(n = 490) | (n = 43+2) | (n = 562) | (n = 88+4) | |
Age (years) | 28.12 ± 4.17 | 28.42 ± 3.97 | 25.07 ± 4.15 | 24.60 ± 4.58 |
BMI (kg/m2) | 21.14 ± 2.92 | 20.88 ± 2.23 | 23.28 ± 4.28 | 22.94 ± 4.20 |
Waist circumference (cm) | 73.82 ± 8.37 | 73.29 ± 6.90 | 79.97 ± 11.45 | 80.36 ± 11.32 |
Waist-to-hip ratio | 0.81 ± 0.06 | 0.81 ± 0.06 | 0.85 ± 0.07 | 0.85 ± 0.07 |
F-G score | 0.25 ± 0.74 | 0.29 ± 0.59 | 1.72 ± 2.04 | 1.87 ± 2.24 |
Acne grade score | 0.14 ± 0.34 | 0.16 ± 0.37 | 0.69 ± 0.92 | 0.38 ± 0.77b |
SBP (mmHg) | 112.61 ± 11.51 | 116.50 ± 10.60a | 114.66 ± 10.81 | 115.97 ± 10.09 |
DBP (mmHg) | 73.77 ± 8.81 | 73.14 ± 6.70 | 75.69 ± 9.08 | 76.39 ± 8.08 |
AOV (ml) | 7.65 ± 2.99 | 7.59 ± 1.71 | 9.96 ± 3.89 | 10.99 ± 5.03 |
Hormonal levels | ||||
TT (nmol/L) | 1.51 ± 0.53 | 1.58 ± 0.51 | 2.35 ± 0.78 | 2.37 ± 0.71 |
SHBG (nmol/L) | 55.14 ± 27.68 | 46.22 ± 15.33 | 35.27 ± 28.02 | 34.25 ± 18.11 |
FAI | 3.27 ± 2.11 | 3.85 ± 2.22 | 9.89 ± 7.26 | 9.10 ± 5.70 |
LH/FSH | 1.24 ± 1.15 | 1.44 ± 2.00 | 2.30 ± 1.30 | 2.27 ± 1.17 |
Oxidative stress parameters | ||||
TOS (nmol H2O2 Equiv./mL) | 11.15 ± 5.18 | 12.19 ± 6.61 | 14.82 ± 10.72 | 15.59 ± 11.12 |
T-AOC (U/ml/min) | 14.52 ± 2.69 | 14.28 ± 2.78 | 15.76 ± 3.09 | 15.99 ± 2.90 |
OSI | 0.79 ± 0.39 | 0.91 ± 0.57 | 0.98 ± 0.78 | 1.02 ± 0.83 |
MDA (nmol/ml) | 3.64 ± 1.06 | 3.88 ± 1.22 | 4.31 ± 1.23 | 4.57 ± 1.71 |
Values are presented as mean ± SD.
AOV, average ovarian volume; BMI, body mass index; DBP, diastolic blood pressure; FAI, free androgen index; F-G score, Ferriman–Gallwey score; FSH, follicle-stimulating hormone; LH, luteinizing hormone; MDA, malondialdehyde; OSI, oxidative stress index; SBP, systolic blood pressure; SHBG, sex hormone-binding globulin; T-AOC, total antioxidant capacity; TOS, total oxidant status; TT, total testosterone.
Comparisons of all parameters were corrected for differences in age and BMI between the 2 subgroups except the parameters of age and BMI.
P < 0.05, compared with the PP genotype subgroup in controls.
P < 0.01, compared with the PP genotype subgroup in PCOS patients.